2024-2033 Denosumab Market: Key Insights on Growth Opportunities
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the Denosumab Market from 2024 to 2033?
The denosumab market is projected to grow from $2.89 billion in 2023 to $3.27 billion in 2024, with a CAGR of 13.2%. This growth stems from advancements in clinical trials, FDA approvals, awareness of bone health, and strategic partnerships.
The denosumab market is expected to grow rapidly, reaching $5.06 billion by 2028 at a CAGR of 11.5%. Growth is driven by rising bone metastases incidence, advancements in cancer therapies, and increased osteoporosis awareness. Major trends include strategic collaborations, integration with digital health solutions, and advancements in biosimilar development.
Claim Your Free Sample of the Global Denosumab Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp
What Key Factors Are Fueling the Growth of the Denosumab Market?
The increasing prevalence of osteoporosis is expected to drive the growth of the denosumab market. Osteoporosis weakens bones, increasing fracture risk. Denosumab treats this condition by inhibiting bone resorption. For example, in December 2023, the Australian Institute of Health and Welfare reported that osteoporosis contributed to 2,366 deaths in 2021. Furthermore, there were 9,500 hospitalizations related to osteoporosis for individuals aged 45 and over during 2021-22. Therefore, the increasing incidence of osteoporosis is driving the denosumab market.
What Are the Major Segments of the Denosumab Market?
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
What New Trends Are Transforming the Denosumab Market?
Major companies in the denosumab market are intensifying efforts to introduce innovative solutions, such as first-line treatments for osteoporosis, to gain a market advantage. First-line treatments are the initial therapeutic approaches recommended for osteoporosis patients. For example, in November 2022, Boan Biotech, a Chinese biotech firm, received approval from China’s National Medical Products Administration for its denosumab biosimilar, Boyoubei, marking it as the first Chinese-developed denosumab injection. It is also being developed for international markets like Europe and the U.S., with plans for global distribution. This drug is recommended as a first-line treatment in various guidelines and can significantly reduce the risk of hip, non-vertebral, and vertebral fractures. Boyoubei is the first biosimilar to Prolia (the original denosumab) approved worldwide.
Order Now for Fast Delivery of Your Denosumab Market Report!
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report
Which Regions Are Driving Growth in the Denosumab Market?
North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Denosumab Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the denosumab market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Denosumab Market Include
1. Denosumab Market Executive Summary
2. Denosumab Market Segments
3. Denosumab Market Size And Template Market Growth Rate
4. Key Denosumab Market Trends
5. Major Denosumab Market Drivers
……
25. Key Mergers And Acquisitions In The Denosumab Market
26. Top Denosumab Companies
27. Denosumab Market Opportunities And Strategies
28. Denosumab Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Anemia and Other Blood Disorder Drugs Global Market Report 2024
Antifungals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Antiglaucoma Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
